Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | CHAT | P28329 | 2/20 | 1.00 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 1.00 |
| ▸ | KAT5 | Q92993 | 2/20 | 1.00 |
| ▸ | KAT2B | Q92831 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coenzyme_A SCHEMBL29350970 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18180012 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL29402901 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL13500623 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL26752 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18682056 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18682057 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18675521 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18033983 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL26753 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | EP300 4723/4885AURKA 1051/4885CHAT 3634/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | EP300 3152/4885AURKA 2/4885CHAT 1472/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | EP300 4467/4885AURKA 984/4885CHAT 3203/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | EP300 4467/4885AURKA 984/4885CHAT 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.